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Objectives: There is increasing interest in studies that examine patient preferences to measure 
health-related outcomes. Understanding patients’ preferences can improve the treatment process 
and is particularly relevant for oncology. In this study, we aimed to identify the subgroup-specific 
treatment preferences of German patients with lung cancer (LC) or colorectal cancer (CRC).
Methods: Six discrete choice experiment (DCE) attributes were established on the basis of a 
systematic literature review and qualitative interviews. The DCE analyses comprised general-
ized linear mixed-effects model and latent class mixed logit model.
Results: The study cohort comprised 310 patients (194 with LC, 108 with CRC, 8 with both types 
of cancer) with a median age of 63 (SD =10.66) years. The generalized linear mixed-effects model 
showed a significant (P,0.05) degree of association for all of the tested attributes. “Strongly 
increased life expectancy” was the attribute given the greatest weight by all patient groups. Using 
latent class mixed logit model analysis, we identified three classes of patients. Patients who were 
better informed tended to prefer a more balanced relationship between length and health-related 
quality of life (HRQoL) than those who were less informed. Class 2 (LC patients with low 
HRQoL who had undergone surgery) gave a very strong weighting to increased length of life. We 
deduced from Class 3 patients that those with a relatively good life expectancy (CRC compared 
with LC) gave a greater weight to moderate effects on HRQoL than to a longer life.
Conclusion: Overall survival was the most important attribute of therapy for patients with 
LC or CRC. Differences in treatment preferences between subgroups should be considered in 
regard to treatment and development of guidelines. Patients’ preferences were not affected by 
sex or age, but were affected by the cancer type, HRQoL, surgery status, and the main source 
of information on the disease.
Keywords: patient preferences, lung cancer, colorectal cancer, Germany, latent class model, 
multi-criteria decision making
Introduction
In 2012, lung cancer (LC) and colorectal cancer (CRC) were two of the most common 
cancers worldwide.1 In developed countries, the 5-year survival rates of patients with 
CRC improved significantly between 1995 and 2009,2 whereas those of patients with 
LC showed only minor improvement.2 The aim of the World Health Organization 
2013–2020 Global Action Plan is to reduce the rate of cancer mortality by improving 
service delivery through early diagnosis and enhanced screening programs.3 The 
prevalence of cancer will rise as a result of earlier detection of the disease; thus, the 
therapeutic options available will gain more attention.
Patients are often confronted with different therapeutic options, which may 
implicate severe adverse effects and uncertain outcomes. Typically, the patients 
evaluate therapeutic options in terms of their ability to prolong survival versus their 
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expected effects on health-related quality of life (HRQoL). 
Consequently, it is important to know what patients prefer 
and what is most important to them during decision making. 
Previous studies have shown a discrepancy between the 
personal preferences of patients and the subjective assess-
ments made by their physicians.4–9 However, we performed 
a systematic literature review which showed that, in general, 
patients do not wish to decide on their therapy personally 
and would prefer their physician to make the decision.10,11 
Here, a conflict can occur, because the therapy that is 
provided to patients should be adjusted to meet their pref-
erences regarding HRQoL and adverse effects. Previous 
studies on other diseases have shown that satisfaction with 
therapy can have a significant effect on disease outcomes 
and further treatment decisions.12–14 On the basis of these 
findings, patient preferences should be examined and 
integrated during decision making regarding cancer therapy.
Furthermore, patient preferences might influence political 
decisions regarding reimbursement for pharmaceuticals. 
In Germany, there is growing interest in preference measure-
ment, following the introduction of the Act on the Reform 
of the Market for Medical Products (Arzneimittelneuord-
nungsgesetz [AMNOG]) in 2011. Although, according to 
the AMNOG, patient-reported outcomes should be taken 
into account during early evaluation of the benefits of new 
pharmaceuticals,15 patient preferences do not play an impor-
tant role in Germany at present. The Federal Joint Committee 
(Gemeinsamer Bundesausschuss) has criticized the lack of 
quality in the scientific evaluations (dossiers) of pharma-
ceutical companies and overruled some patient-reported 
outcomes.16 Hence, our findings might influence the ongoing 
debate about the evidence provided by studies of patient pref-
erences and be relevant to the German health care system.
The aim of the study was to examine the therapy pref-
erences of German patients with LC and CRC. These two 
types of cancer show high prevalence rates in Germany and 
worldwide. However, their divergent overall survival rates 
and disease-related adverse effects might lead to different 
therapy preferences among patients with LC and CRC. 
In addition, we wanted to identify subgroups of patients 
that shared similar preferences, irrespective of the cancer 
type. Members of these homogenous subgroups might share 
same sex, age, or educational level. Comparison of the two 
different cancer types and the resulting patient (subgroup-
specific) preferences represents the added value of our study. 
Consequently, our aim is to confirm the importance of patient 
preference studies and their need for implementation in 
health care. These data could also help physicians to make 
clinical decisions by differentiating among the preferences 
of various subgroups of patients and might enable improve-
ment of therapy guidelines.
Patients and methods
Derivation of attributes and discrete 
choice tasks
In a discrete choice experiment (DCE), two (or more) alter-
native scenarios are presented. Each alternative (profile) is 
described by several attributes.17 The participant must choose 
which of the profiles they prefer.18
The whole study process is illustrated in Supplementary 
material. First, we conducted a systematic literature review 
to identify the key topics related to cancer therapy for use 
in subsequent qualitative interviews.10,11 The systematic 
literature reviews identified 15 relevant studies of prefer-
ences with respect to therapy for CRC and 17 relevant 
studies of preferences with respect to therapy for LC. 
The most important concerns for patients with CRC were 
diarrhea, nausea, pain, requirement of a stoma, role func-
tioning, emotional functioning, toxicity of chemotherapy, 
life expectancy/overall survival, and taking medication at 
home.10,11 For patients with LC, the most important concerns 
identified by the literature review were: fatigue, diarrhea, 
nausea, pain, role functioning, intensity of treatment, overall 
survival, and HRQoL versus length of life.10,11 Second, we 
conducted guided qualitative interviews that were based 
on the results of our systematic literature review. We 
interviewed 18 patients with LC and 17 patients with CRC, 
and then conducted content analyses (Aumann et al19 for 
interviews with LC patients and [Damm et al: Supplemen-
tary material] for interviews with CRC patients). We used 
the inductive and deductive categories from the content 
analysis to identify the main topics: adverse effects, social 
quality of life, emotional quality of life, and organization. 
Further subcategories (10–23) were established for each 
main topic. We sorted the identified categories on the basis 
of the frequency with which they were mentioned, separated 
by patients with LC and patients with CRC (Supplementary 
material). Subsequently, we chose the most frequently men-
tioned categories and determined whether they overlapped 
with respect to meaning. We aimed to cover a large spec-
trum of categories, while simultaneously ensuring minimal 
overlap or correlation between the attributes. To this end, 
we aggregated the categories into topics that could serve 
as attributes. Another restriction was the required total 
number of attributes (five to nine) to prevent overstraining 
of the interviewee.20
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To generate the questionnaire, we identified five attributes 
from the most important categories that did not overlap in 
their meanings and added the attribute of overall survival 
from the literature review. We realized that the resulting 
attributes were similar for patients with CRC and those with 
LC. Therefore, we decided to use the same attributes for both 
groups of cancer patients. The first attribute that we exam-
ined was the efficacy of therapy, measured as additional life 
expectancy after diagnosis. Given that the time of survival 
can vary considerably between patients with CRC and those 
with LC, we decided to examine the objective values rather 
than specific time periods. Adverse effects were separated 
into three attributes of “physical capacity”, “appearance”, 
and “food intake and digestion”. Given this separation, we 
expected no overlaps between the attributes. The different 
possible levels assigned to the attributes were derived from 
the experiences of the interviewees and were divided into 
“minor”, “medium”, and “strong” effects. In the interviews, 
“physical capacity” was described as tiredness, decreased 
physical ability, and overall physical exhaustion. We carried 
these descriptions over into the questionnaire. The symptoms 
that were associated most commonly with “appearance” were 
hair loss, weight loss, and eczema. The fifth attribute identi-
fied was “waiting time in the clinic or therapy-associated 
practice”. It corresponded to the time that patients had to 
spend waiting during therapy, for example, waiting time 
between blood tests and the start of chemotherapy. The 
final attribute referred to the provision of a “guide” who was 
independent and would provide information on the services 
and assistance associated with treatment for LC or CRC. 
During the interviews, the patients were highly critical of 
the treatment process and its organization. One of the more 
frustrating factors for the patients was the lack of informa-
tion, rather than the waiting time itself, and more specifi-
cally, the strain that resulted from the lack of information on 
disease-associated proposals and paperwork. Some patients 
also mentioned that they had to coordinate communication 
between their doctors and their health insurance providers. 
Therefore, for the purpose of the questionnaire, we introduced 
the concept of a guide who would provide support for the 
patients either personally or over the telephone. This “guide” 
was defined as a free-of-charge service to reduce the effect 
of any monetary concerns that the patients might have. There 
were only two possible levels for this attribute: “yes” or “no”. 
The final attributes and levels, including a description of the 
study participants, are presented in Table 1.
We used the Statistical Analysis Software % ChoicEff 
macro to construct choice sets.21 We used two versions of 
the questionnaire because blocking certain choice sets was 
found to reduce the burden on patients’ decision making. 
The first choice set enabled us to test patients’ understanding 
of the DCE method because it included a dominant profile. 
In total, we provided 10 choice sets of DCE tasks to each 
participant (for an example of choice set, see Supplementary 
material).
ethical standards
The patients provided written informed consent to 
participate. Approval for this study was obtained from 
the ethics committee of the Hannover Medical School 
(Nr 1518–2012) and the Medical Association of Lower 
Saxony, the University of Goettingen, and the University 
Hospital Tuebingen.
Development of the questionnaire
We conducted a pretest to ensure that the final question-
naire could be understood easily by the patients. The pretest 
showed that most patients could not answer questions about 
their disease state or therapy goals (palliative, adjuvant, 
maintenance). Therefore, this question was excluded from 
Table 1 Descriptions of attributes used in the questionnaire
Attribute  Levels
life expectancy life expectancy at the time 
of diagnosis with regard to 
mean survival in patients 
with lung or colon cancer 
(average of all cancer stages)
– not increased
– slightly increased
– strongly increased 
Physical 
capacity
Decrease in physical capacity 
that influences everyday 
life, for example, being out 
of breath quickly, being 
tired, sitting down often, or 
sleeping during the day
– normal
– Moderately 
decreased
– strongly decreased
Appearance changes in appearance 
caused by the disease itself 
or the treatment (adverse 
effects). Possible changes 
include hair loss, eczema, 
or weight loss
– Unchanged
 (no visible changes)
– slightly changed
– Significantly changed
Food intake 
and digestion
Problems with food intake 
or digestion, such as loss of 
appetite, nausea, emesis, 
or diarrhea
– no problems/normal
– Minor problems
– severe problems
Waiting time 
(in the clinic)
The time spent waiting 
in the clinic or practice 
for your therapy. This 
could be, for example, 
the waiting time between 
blood tests and the start of 
chemotherapy
– no waiting time
– Moderate waiting 
time
– long waiting time
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the questionnaire because we were not allowed to access 
medical records.
The final questionnaire consisted of a section on patient 
information, a form regarding informed consent, a definition 
of the attributes, Likert-scale questions about the therapy 
attributes (from 1, “very unimportant” to 5, “very impor-
tant”), 10 DCE sets, sociodemographic questions, and the 
cancer-specific HRQoL questionnaire developed by the 
European Organization for Research and Treatment of 
Cancer (EORTC), termed the EORTC QLQ-C3022,23 (for an 
overview of the variables, see Supplementary material).
study population
Patients attending specialized ambulatory practices or the 
departments of pneumology or gastroenterology at eight 
hospitals in Germany were invited to participate in our study. 
The cooperating institutions were (for further information, 
see Supplementary material):
•	 Hannover Medical School, Department of Pneumology 
and Department of Gastroenterology, Hepatology and 
Endocrinology, Hannover;
•	 Johannes Wesling Medical Center, Department of 
Hematology, Oncology, Hemostaseology, and Palliative 
Care UKRUB, University of Bochum, Minden;
•	 Lung Cancer Center, Hospital Region Hannover;
•	 Clinic for Visceral, General, and Transplant Surgery, 
Surgical Study Center, University Hospital Tuebingen;
•	 Ambulatory Oncological Center, Hannover;
•	 Group Practice for Internal Medicine and Pulmonology, 
Celle;
•	 Interdisciplinary Short-term Oncology, Department of 
Hematology and Medical Oncology, Goettingen; and
•	 Group Practice for Hematology and Oncology, Hannover.
The participating clinics administered the questionnaire 
to patients with LC and CRC of all disease stages who were 
aged $18 years and had finished at least one cycle of chemo-
therapy (including in the past). Both modes of chemotherapy 
administration (tablet and infusion) were eligible for inclu-
sion in the study.
In addition, we initiated an online survey with the same 
inclusion criteria. The link to the survey was distributed via 
the Facebook page of the German self-help organization 
ILCO, the Felix Burda Colon Cancer Website and Facebook 
page, the Center for Health Economics Research Hannover 
Facebook page, and the mailing lists of regional self-help 
groups for patients with CRC and LC.
The recruitment period was from September 2014 to 
October 2016. Neither patients nor physicians received any 
incentives for participating in the study. All participants 
provided informed consent. The minimum required sample 
size was 196, which was calculated in accordance with the 
study by de Bekker-Grob et al.24
Approval for the study was obtained from the ethics com-
mittees of the Hannover Medical School (reference number: 
1518–2012), Medical Association of Lower Saxony, University 
of Goettingen, and University Hospital Tuebingen.
Data analyses
Following completion of the survey, we cleansed the data set 
(testing for impossible values, systematic missings, import 
errors, and so on) and calculated descriptive statistics for the 
variables (median, SD, percentages). The HRQoL was calcu-
lated using symptom scales, functional scales, and the global 
health score from the EORTC QLQ-C30 questionnaire.25 
We applied logistic regression analyses to determine factors 
(independent variables) that influenced the choices made 
between the profiles of each choice set (dependent variables). 
The utility of each profile was calculated using Formula 1 in 
Supplementary material.
We used a generalized linear mixed-effects model (GLMM) 
to examine the effects of multiple answers for each individual 
choice set (serial_no). We calculated the GLMM for patients 
with CRC and LC separately, so that any differences between 
the two patient groups could be identified based on Hauber et al26 
and McCulloch et al27 (Formula 2 in Supplementary material).
Finally, we used the latent class mixed logit model 
(LCMLM) with a different number of classes to identify, 
strictly on the basis of the data, possible sample subgroups 
with specific characteristics (eg, sociodemographic status, 
disease-specific parameters). These subgroup characteristics 
were presented in the so-called class-membership effects 
model. An overview of the variables tested for all models 
is provided in Supplementary material. The final model 
is shown in Formula 3 in Supplementary material.
The β-coefficients from the GLMM and LCMLM rep-
resent the weights of the utility for choosing the profile. 
β-coefficients .0 indicated that an attribute level was 
preferred, whereas coefficients ,0 indicated that it was 
disfavored. Alternatively, coefficients ,0 suggested that an 
attribute level was accepted in order to gain advantages 
in other attributes. The results for the β-coefficients were 
assumed to be significant at a P-value #0.05.
The models were tested with different independent vari-
ables and, finally, lean models were targeted. Akaike and 
Bayesian information criteria were used to identify the model 
with the best fit for the data. All analyses were conducted 
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with R statistics 3.1.2 (The R Foundation for Statistical 
Computing, Vienna, Austria), using the packages “lme4” 
(for GLMM) and “lcmm” (for LCMLM).
Results
Descriptive statistics
In total, 369 patients participated initially in the study, 
but this number decreased to 310 participants after data 
cleansing. The distribution of mean age and sex did not differ 
significantly between the included and excluded groups of 
participants. Table 2 shows the characteristics of the patients. 
Given that only eight patients had both types of cancer, we 
did not assess their preferences separately.
The cohort was younger than the average ages of patients 
with LC and CRC in Germany.28,29 However, the general sex 
distribution of patients with LC and CRC in Germany was 
similar to that evident in our sample.
Multivariate models
generalized linear mixed-effects model
Figure 1 shows the results of the three GLMMs (LC, CRC, full 
sample). A strong increase in life expectancy was the attribute 
level that was given the most weight by all three groups 
(β
LC,OS2
 =2.56, β
CRC,OS2
 =1.77, β
ful,OS2
 =2.17; all P,0.001). For 
patients with LC, the level of “normal physical capacity” 
was given greater weight than a “moderate” or “strong 
decrease” in physical capacity (β
LC,PC0
 =0.79, β
LC,PC1
 =0.34, 
β
LC,PC2
 =−1.13; P,0.001). However, both the patients with 
CRC and the full sample rated “normal physical capacity” 
more highly than “moderately decreased capacity”, although 
this was not statistically significant. With regard to “changes 
in appearance”, all patient groups gave a greater weight to a 
“slightly changed appearance” than to an “unchanged appear-
ance”. “No problems” or “minor problems” with food intake 
and digestion were rated slightly higher by patients with LC 
than those with CRC (β
LC,FI0
 =0.83, P,0.001; β
CRC,FI0
 =0.49, 
P,0.001; β
LC,FI1
 =0.18, P=0.05; β
CRC,FI1
 =−0.14, P=0.15). 
“No waiting time” (reference category) was given slightly 
less weight by the full sample than by patients with CRC 
(β
full,WT0
 =0.25, β
CRC,WT0
 =0.35; P,0.001). In general, the 
preferences of the three groups were very similar (see also 
Supplementary material).
latent class mixed logit model
The LCMLM identified three different classes of patients 
with specific class-membership effects (Table 3; for a graphi-
cal presentation, see Supplementary material). The first class 
showed a strong preference for “clearly longer survival” 
(β
cl1,OS2
=1.56, P,0.001). In contrast, this class disfavored 
“slightly longer survival” (β
cl1,OS1
=−0.2, P,0.001). Patients 
in Class 1 accepted a “moderately decreased physical capac-
ity” compared with a “normal physical capacity”. In addition, 
Table 2 sample characteristics of included participants
Characteristic CRC LC Both Total
sample size 108 194 8 310
sex 49.6% men 69.80% men 40% men 62.16% men
Median age (sD) in years 59.5 (12.66) 63 (10.58) 48.5 (8.90) 63 (10.66)
cancer type
crc 100% 0% 0% 35.04%
lc 0% 100% 0% 63.03%
Both 0% 0% 100% 1.93%
Median disease duration (sD) in years 2 (5.92) 1 (2.14) 7.5 (7.20) 1 (4.16)
Marital status
single 8.6% 10.0% 0% 9.3% 
Married 69.6% 70.3% 80.0% 70.2% 
Divorced 13.2% 13.9% 0.2% 13.8% 
Widowed 8.6% 5.7% 0% 6.6% 
School-leaving qualifications
none 2.3% 1.6% 40.0% 2.5%
Primary school 33.0% 48.2% 2.0% 42.4%
secondary school 34.1% 30.0% 40.0% 31.6%
high school 30.7% 20.1% 0% 23.4%
Median global health status (sD)
scale from 0 (worst) to 100 (best) 66.7 (22.69) 58.3 (20.44) 58.3 (20.56) 66.7 (21.56)
Median hrQol (sD)
scale from 1 (very bad) to 7 (excellent) 5 (1.48) 5 (1.27) 5 (0.87) 5 (1.35)
Abbreviations: crc, colorectal cancer; lc, lung cancer; hrQol, health-related quality of life.
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this class was willing to accept “moderate” and “long wait-
ing times”. Patients in Class 2 showed a preference for both 
“clearly longer” and “slightly longer survival” (β
cl2,OS2
 =0.64, 
β
cl2,OS1
 =0.36; P,0.001). However, “physical capacity”, 
“appearance”, and “food intake and digestion” were also 
important attributes for this class. In this model, a decrease 
from “clearly longer” to “slightly longer survival” (β
OS2
: 
0.64−β
OS1
: 0.36=0.28) could be compensated for by a change 
from a “strong decrease” to a “moderate decrease” in physical 
capacity (β
PC2
: −0.66−β
PC1
: 0.34=−1). Consequently, patients 
in Class 2 were willing to trade prolonged survival for smaller 
decreases in physical capacity. We cannot interpret the pref-
erences of Class 3 in regard to “overall survival” because the 
results were not statistically significant (P.0.05). This group 
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Figure 1 results of mixed logit models.
Notes: Triangular shape, full sample; rectangular shape, lung cancer; diamond shape, colon cancer; random intercept: serial_no.
Table 3 latent class mixed logit model results – attribute preferences
Attribute Level Class 1 Class 2 Class 3
βcl1 P-value βcl2 P-value βcl3 P-value
intercept ne 0.07 0.05
Overall survival clearly longer 1.56 0.00 0.64 0.00 0.07 0.27
slightly longer −0.20 0.00 0.36 0.00 0.07 0.33
not longer (ref) −1.36 −1.00 −0.14
Physical capacity normal 0.08 0.02 0.32 0.00 −0.49 0.00
Moderate decrease 0.28 0.00 0.34 0.00 0.57 0.00
strong decrease (ref) −0.35 −0.66 −0.08
Appearance Unchanged −0.05 0.16 0.14 0.00 −0.58 0.00
slightly changed −0.01 0.85 0.37 0.00 0.34 0.00
Significantly changed (ref) 0.06 −0.51 0.25
Food intake and 
digestion 
no problems 0.17
−0.01
0.00 0.42 0.00 −0.14
−0.52
0.03
Minor problems 0.89 0.21 0.00 0.00
strong problems (ref) −0.17 −0.63 0.66
Waiting time none −0.18 0.00 −0.04 0.25 0.04 0.52
Moderate 0.02 0.51 0.29 0.00 −0.20 0.00
long (ref) 0.16 −0.26 0.16
guide Yes −0.03 0.21 0.22 0.00 0.07 0.14
no (ref) 0.03 −0.22 0.04 −0.07 0.31
Notes: Age (standardized), sex, cancer type, hrQol, disease duration (centered by mean), radiation therapy, and change of appearance are used as class membership effects.
Abbreviations: cl, class; hrQol, health-related quality of life; ne, not estimated; ref, reference.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
95
.1
58
.7
2 
on
 2
0-
O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1653
Therapy preferences of patients with lung and colon cancer
disfavored the most favorable levels of the attributes “physi-
cal capacity”, “appearance”, and “food intake problems” 
(β
cl3,PC0
	=−0.49, β
cl3,AP0
 =−0.58, β
cl3,FI0
 =−0.14, β
cl3,FI1
 =−0.52; 
P,0.05). However, they gave a greater weight to the middle 
levels for “physical capacity” and “appearance” than to the 
other levels.
Next, we investigated the class-membership effects for 
the three classes. Of all the patients, 42.13% were assigned 
to Class 1, 47.24% to Class 2, and 10.63% to Class 3. The 
differences between classes 1 and 2 (referenced against 
Class 3) are presented in Table 4. Patients in classes 1 and 2 
did not differ significantly from patients in Class 3 in terms of 
age, sex, or duration of disease. Classes 1 and 2 had a lower 
proportion of patients with CRC than Class 3 (β
cl1,CRC
 =−2.21, 
β
cl2,CRC
 =−1.69; P,0.05). The classes also differed in terms 
of their therapy experiences: patients in Class 1 were more 
likely to have undergone surgery than those in classes 2 
and 3 (β
cl1,treat_1
 =1.997, β
cl2,treat_1
 =1.7; P,0.05). We also 
observed a difference between the classes with regard to 
the main source of information on their disease. Patients 
in classes 1 and 2 were more likely to obtain relevant 
information from their physician than patients in Class 3 
(β
cl1,info_1
 =2.58, β
cl2,info_1
 =2.71; P,0.05). Other sources of 
information (other patients, books, the Internet, self-help 
groups) were shown to have no significant influence on the 
model. In addition, patients in Class 1 showed significantly 
worse HRQoL outcomes (β
cl1,LQ_30_s
 =−0.54, P=0.04) than 
patients in the other classes.
Discussion
We systematically investigated the differences in the therapy 
preferences of patients with two divergent types of cancer. 
Whereas previous studies have examined the therapy pref-
erences of patients with different disease states of the same 
cancer type, we compared the preferences of patients with 
CRC and LC. In our first model (mixed logit model), we 
found that patients with LC and CRC had almost the same 
preferences for therapy attributes and differed only slightly 
in their preferences. In the strictly data-driven LCMLM, we 
found that cancer type, current HRQoL status, and the source 
of information were important for the therapy preferences.
Subsequently, we will compare our findings in detail 
with the current knowledge. In accordance with other studies 
that examined the therapy preferences of patients with LC, 
“life expectancy” was the most important attribute.11,30–32 
This might be due to the shorter life expectancy of patients 
with LC compared with that of patients with CRC. Another 
important attribute identified in previous studies was “tumor-
associated symptoms”.30 However, previous studies are 
quite inconsistent in terms of what they consider to be the 
chief adverse effect of cancer treatment. For example, one 
study identified fatigue and tiredness as the two attributes 
of most consequence, whereas another found that the most 
consequential attributes were nausea and vomiting.30,31 
Both assessed the preferences of patients with (advanced) 
non-small cell LC, which might have strongly influenced 
the overall results. In our study, we found that “slightly 
changed appearance” and “no problems in food intake and 
digestion” were the attribute levels related to adverse effects 
that were given the greatest weight by patients with CRC 
and LC, respectively. This might be explained by the fact 
that patients with CRC expect to experience disturbances of 
food intake and digestion.
Few studies have found that sociodemographic charac-
teristics, such as sex or age, do not influence preferences 
for cancer therapy.9,30,33 Other studies have reported that 
sociodemographic characteristics do influence the prefer-
ences of patients, but they did not include associations 
Table 4 class-membership effects of latent class mixed logit models (reference: class 3)
Fixed-effects class-membership 
model
Class 1 Class 2
Coefficient Standard 
error
P-value Coefficient Standard 
error
P-value
intercept 2.609 1.380 0.059 1.875 1.368 0.171
Age (mean centered) 0.021 0.029 0.485 0.035 0.029 0.226
sex (ref =	male) −1.003 0.728 0.168 −0.497 0.714 0.486
crc (ref = lc) −2.214 0.786 0.005 −1.686 0.757 0.026
Both cancers (ref =	lc) −2.074 2.008 0.301 −1.790 2.021 0.376
hrQol (mean centered) −0.537 0.267 0.044 −0.403 0.263 0.125
Disease duration (mean centered) 0.000 0.069 0.998 −0.037 0.072 0.609
surgery (ref = no) 1.997 0.796 0.012 1.701 0.778 0.029
radiation (ref =	no) −1.069 0.691 0.122 −0.796 0.678 0.241
changes in appearance (ref =	no) −0.322 0.336 0.338 −0.372 0.332 0.263
information: physician 2.575 0.784 0.001 2.714 0.738 0.000
Note: Significant values are shown in bold.
Abbreviations: crc, colorectal cancer; hrQol, health-related quality of life; lc, lung cancer; ref, reference.
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between therapy preferences and the actual health status of 
patients.34,35 Two previous studies did not find a difference 
in preference based on patients’ proximity to death.32,34,35 
However, we observed that having undergone surgery had 
a noticeable influence on patients’ preferences. Therapeutic 
guidelines recommend surgery at an early disease stage in 
patients with comorbidities (when the tumor is operable). 
Therefore, we can assume that patients with a poor prognosis 
due to LC and a low HRQoL would prefer to increase their 
length of life when the disease is detected early and surgery 
is an option.
In summary, our study yielded several novel findings. 
Patients who were better informed tended to prefer a more 
balanced relationship between length and quality of life, 
as compared with less-informed patients. The physicians 
involved in our study confirmed that they emphasized not 
only length of life, but also HRQoL as important consid-
erations in their consultations with patients. The influence 
of physicians on the preferences of patients should be 
examined in further research. The second finding was that 
another subgroup (patients with LC and a low HRQoL who 
had undergone surgery) gave a great weight to increased 
length of life. Finally, we deduced from patients in Class 
3 that those with a relatively good life expectancy (CRC 
compared with LC) gave a greater weight to moderate 
effects on HRQoL (physical capacity, appearance) than to 
a longer life.
However, our study was limited in terms of the unbal-
anced distribution of patients between the subgroups, which 
resulted in a small number of patients in Class 3, even though 
the recruitment period was extended. Furthermore, the results 
suggest that the online survey was inappropriate for some 
patients with CRC and LC, particularly patients of advanced 
age. Alternatively, inappropriate online distributors were 
used for this process of recruiting older patients. Overall, it 
appears that older patients were less willing to participate in 
our study than younger ones. Recruiting patients with LC and 
CRC at clinics or hospitals might also have biased the study 
sample, because patients who were not undergoing therapy 
were excluded. Given that patients were often unaware of 
their current disease stage or type of chemotherapy (pal-
liative, adjuvant, maintenance), we were unable to include 
questions concerning this information. It might be possible 
to estimate disease stage on the basis of self-assessed health 
and surgery status, although the results can be incomplete or 
misleading.36–40 In addition, surgery can be initiated at differ-
ent disease stages, such as after diagnosis or in the case of 
disease progression. This means that the “treatment” variable 
should not be interpreted without further information. Conse-
quently, future studies should obtain patient records to iden-
tify any possible associations between stage, therapy goals, 
and therapy preferences. Although we defined each attribute 
at the beginning of the questionnaire, we could not control 
for how patients interpreted the attributes and levels in their 
own way and as a result of their own disease experiences. 
However, we would have detected other results if other or 
further attributes had been included in the DCE tasks. This 
disadvantage of the DCE method is also discussed in other 
methodologic publications.18,41
The classes identified by LCMLM cannot be accounted 
for by typical sociodemographic aspects. Therapy should be 
adjusted to accommodate these three classes. Some class-
specific preferences might be accommodated easily (the 
provision of a guide or shorter waiting times) and might 
compensate for some of the disadvantages of chemotherapy. 
Consequently, differences among the classes should be 
recognized in individual treatment options. This implies 
that physicians need time to explain and discuss the therapy 
alternatives with patients. Our findings can be used to develop 
treatment guidelines and to assess the benefits of pharma-
ceuticals. However, in accordance with previous studies, 
the ability to prolong their survival was the most important 
therapy attribute of a given therapy for patients, irrespective 
of the cancer type.
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